Hemoglobin overexpression and splice signature as new features of inflammatory breast cancer?
暂无分享,去创建一个
F. Bertucci | S. V. van Laere | P. de la Grange | D. Gentien | M. Caly | F. Lerebours | J. Guinebretière | C. Callens | S. Vacher | X. Liang | S. Rondeau | M. Caly | L. Bièche | S. V. Laere | Florence Lerebours | Sophie Vacher | François Bertucci | P. D. L. Grange | L. Bièche | X. Liang
[1] H. Ford,et al. Cellular Plasticity in Breast Cancer Progression and Therapy , 2020, Frontiers in Molecular Biosciences.
[2] J. Zhai,et al. Expression signatures and roles of microRNAs in inflammatory breast cancer , 2019, Cancer Cell International.
[3] S. Vacher,et al. Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer , 2018, Breast Cancer Research.
[4] A. Angelucci,et al. Non-conventional role of haemoglobin beta in breast malignancy , 2017, British Journal of Cancer.
[5] W. Woodward,et al. Inflammatory breast cancer: a model for investigating cluster-based dissemination , 2017, npj Breast Cancer.
[6] M. Cristofanilli,et al. Mutational studies on single circulating tumor cells isolated from the blood of inflammatory breast cancer patients , 2017, Breast Cancer Research and Treatment.
[7] Sridhar Ramaswamy,et al. Expression of β-globin by cancer cells promotes cell survival during blood-borne dissemination , 2017, Nature Communications.
[8] C. Ghigna,et al. EMT and stemness: flexible processes tuned by alternative splicing in development and cancer progression , 2017, Molecular Cancer.
[9] F. Bertucci,et al. Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study. , 2016, The Lancet. Oncology.
[10] V. Velculescu,et al. Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors , 2016, Molecular Cancer Therapeutics.
[11] Jean Paul Thiery,et al. EMT: 2016 , 2016, Cell.
[12] P. Stephens,et al. Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations , 2015, Breast Cancer Research and Treatment.
[13] F. Bertucci,et al. Decreased expression of ABAT and STC2 hallmarks ER‐positive inflammatory breast cancer and endocrine therapy resistance in advanced disease , 2015, Molecular oncology.
[14] J. Bonneterre,et al. Pathological Response and Circulating Tumor Cell Count Identifies Treated HER2+ Inflammatory Breast Cancer Patients with Excellent Prognosis: BEVERLY-2 Survival Data , 2014, Clinical Cancer Research.
[15] Daniel Birnbaum,et al. Genomic profiling of inflammatory breast cancer: a review. , 2014, Breast.
[16] Rosette Lidereau,et al. miRNA expression profiling of inflammatory breast cancer identifies a 5‐miRNA signature predictive of breast tumor aggressiveness , 2013, International journal of cancer.
[17] Randa El-Zein,et al. Genomic and expression analysis of microdissected inflammatory breast cancer , 2013, Breast Cancer Research and Treatment.
[18] F. Bertucci,et al. Uncovering the Molecular Secrets of Inflammatory Breast Cancer Biology: An Integrated Analysis of Three Distinct Affymetrix Gene Expression Datasets , 2013, Clinical Cancer Research.
[19] E. Wang,et al. Global Profiling of Alternative Splicing Events and Gene Expression Regulated by hnRNPH/F , 2012, PloS one.
[20] A. Angelucci,et al. Increased expression of a set of genes enriched in oxygen binding function discloses a predisposition of breast cancer bone metastases to generate metastasis spread in multiple organs , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[21] C. Reddy,et al. Modern outcomes of inflammatory breast cancer. , 2012, International Journal of Radiation Oncology, Biology, Physics.
[22] John Quackenbush,et al. A three-gene model to robustly identify breast cancer molecular subtypes. , 2012, Journal of the National Cancer Institute.
[23] Nicholas C. Flytzanis,et al. An EMT–Driven Alternative Splicing Program Occurs in Human Breast Cancer and Modulates Cellular Phenotype , 2011, PLoS genetics.
[24] G. Kristiansen,et al. Old proteins – new locations: myoglobin, haemoglobin, neuroglobin and cytoglobin in solid tumours and cancer cells , 2011, Acta physiologica.
[25] S. Merajver,et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] Daniel Birnbaum,et al. High-Resolution Comparative Genomic Hybridization of Inflammatory Breast Cancer and Identification of Candidate Genes , 2011, PloS one.
[27] Lajos Pusztai,et al. A clinically relevant gene signature in triple negative and basal-like breast cancer , 2010, Breast Cancer Research.
[28] Patrick Pauwels,et al. Array-Based DNA Methylation Profiling for Breast Cancer Subtype Discrimination , 2010, PloS one.
[29] Seigo Nakamura,et al. Molecular targets for treatment of inflammatory breast cancer , 2009, Nature Reviews Clinical Oncology.
[30] P. Levine,et al. Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer , 2009, Nature Cell Biology.
[31] Pierre de la Grange,et al. A new advance in alternative splicing databases: from catalogue to detailed analysis of regulation of expression and function of human alternative splicing variants , 2007, BMC Bioinformatics.
[32] Didier Auboeuf,et al. FAST DB: a website resource for the study of the expression regulation of human gene products , 2005, Nucleic acids research.
[33] R. Tibshirani,et al. Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[34] Elisabeth Remy,et al. GeneANOVA-gene expression analysis of variance , 2002, Bioinform..
[35] I. Bièche,et al. Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. , 1999, Clinical chemistry.